graphic
News > Companies
FDA rejects Novartis drug
June 18, 2001: 8:26 p.m. ET

FDA refuses to approve Novartis/BMY irritable bowel syndrome treatment
graphic
graphic graphic
graphic
NEW YORK (CNNfn) - The U.S. Food and Drug Administration failed to approve a Novartis and Bristol-Myers Squibb drug for the treatment of irritable bowel syndrome.

Novartis said Monday the FDA requested more data about IBS treatment Zelnorm. The company said it is considering options, along with Bristol-Myers (BMY: Research, Estimates).

There is currently no effective treatment for IBS, Novartis said.

Dain Rauscher Wessels said in a research note it does not expect Zelnorm to be approved before 2003 if a new study is required and maintained its "neutral" rating on Bristol-Myers.

Shares of Bristol-Myers lost 44 cents to $55.06 Monday. graphic

  RELATED STORIES

DuPont sells drug unit - June 7, 2001




graphic


© 2009 Cable News Network. A Time Warner Company. All Rights Reserved. Terms under which this service is provided to you. Privacy Policy
Live Quotes automatically refresh, but individual equities are delayed 15 minutes for Nasdaq, and 20 minutes for other exchanges. Market indexes are shown in real time, except for the DJIA, which is delayed by two minutes. All times are ET.
* : Time reflects local markets trading time. † - Intraday data delayed 15 minutes for Nasdaq, and 20 minutes for other exchanges. Disclaimer
Copyright © 2009 BigCharts.com Inc. All rights reserved. Please see our Terms of Use.
MarketWatch, the MarketWatch logo, and BigCharts are registered trademarks of MarketWatch, Inc.
Intraday data provided by Interactive Data Real-Time Services and subject to the Terms of Use.
Intraday data is at least 20-minutes delayed. All times are ET.
Historical, current end-of-day data, and splits data provided by Interactive Data Pricing and Reference Data.
Fundamental data provided by Morningstar, Inc..
SEC Filings data provided by Edgar Online Inc..
Earnings data provided by FactSet CallStreet, LLC.
Home | Contact Us | Advertise with Us | Corrections | Career Opportunities | Site Map
RSS | Email Delivery | Portfolio | Podcasts | Mobile | Widgets | User Preferences | Special Sections
| Magazine Customer Service | Download Fortune Lists | Reprints | Conferences | Business Leader Council